Renal and Metabolic Toxicities Following Initiation of HIV-1 Treatment Regimen in a Diverse, Multinational Setting: A Focused Safety Analysis of ACTG PEARLS (A5175)

REFERENCES

• Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observa-tional study. Lancet. 2003;362(9377):22–29.
   PubMed Web of Science ®Google Scholar
• Madec Y, Laureillard D, Pinoges L, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS. 2007;21(3):351–359.
   PubMed Web of Science ®Google Scholar
• Corey DM, Kim HW, Salazar R, et al. Brief report: Effective-ness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr. 2007;44(4):451–455.
   PubMed Web of Science ®Google Scholar
• Ford N, Calmy A. Improving first-line antiretroviral ther-apy in resource-limited settings. Curr Opin HIV AIDS. 2010;5(1):38–47.
   PubMed Web of Science ®Google Scholar
• Menzies NA, Berruti AA, Blandford JM. The determinants of HIV treatment costs in resource limited settings. PLoS One. 2012;7(11):e48726.
   PubMed Web of Science ®Google Scholar
• Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis. 2005;41(3):376–385.
   PubMed Web of Science ®Google Scholar
• Amole CD, Brisebois C, Essajee S et al. Optimizing antiret-roviral product selection: A sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries. J Acquir Immune Defic Syndr. 201157:5100–S103.
   Google Scholar
• US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 2013.
   Google Scholar
• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection. 2012 recommendations of the International Antiviral Society—USA Panel. JAMA. 2012;308(4):387–402.
   PubMed Web of Science ®Google Scholar
• Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 revision. Geneva: World Health Orga-nization; 2010. http://whcilibdoc.who.int/publica-tions/2010/9789241599764_eng.pdf. Accessed November 2013.
   Google Scholar
• Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV Infection. Geneva: World Health Organization; 2013. www.who.int/hiv/pub/guide-lines/arv2013. Accessed December 2013.
   Google Scholar
• Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev. 2010;3.
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivu-dine, and efavirenz for HIV. N Engl J Med. 2006;354(3): 251–260.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir diso-proxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47(1):74–78.
   PubMed Web of Science ®Google Scholar
• Rey D, Hoen B, Chavanet P, et al. High rate of early viro-logical failure with the once-daily tenofovir/lamivudine/ nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother. 2009;63(2):380–388.
   PubMed Web of Science ®Google Scholar
• Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis. 2000;30(Suppl 2):S96–116.
   PubMed Web of Science ®Google Scholar
• Campbell TB, Smeaton LM, Kumarasamy N et al. Effi-cacy and safety of three antiretroviral regimens for initial treatment of HIV-1: A randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9 (8):e1001290.
   PubMed Web of Science ®Google Scholar
• Mutimura E, Stewart A, Rheeder P, Crowther NJ. Meta-bolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46 (4):451–455.
   PubMed Web of Science ®Google Scholar
• Parakh A, Dubey AP, Kumar A, Maheshwari A. Lipodystro-phy and metabolic complications of highly active antiretro-viral therapy. Indian J Pediatr. 2009;76(10):1017–1021.
   PubMed Web of Science ®Google Scholar
• Hammond E, McKinnon E, Nolan D. Human immunode-ficiency virus treatment-induced adipose tissue pathol-ogy and lipoatrophy: Prevalence and metabolic conse-quences. Clin Infect Dis. 2010;51(5):591–599.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleo-side and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109–1118.
   PubMed Web of Science ®Google Scholar
• Van Vonderen MGA, van Agtmael MA, Hassink EAM, et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One. 2009;4 (5):e5647.
   PubMed Web of Science ®Google Scholar
• Dlamini J, Ledwaba L, Mokwena N, et al. Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa. Antivir Ther. 2011;16(4):605–609.
   PubMed Web of Science ®Google Scholar
• Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496–505.
   PubMed Web of Science ®Google Scholar
• Smurzynski M, Collier AC, Koletar SL, et al. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): Rationale, design, and baseline characteristics. HIV Clin Trials. 2008;9(4):269–282.
   PubMed Web of Science ®Google Scholar
• Albrecht H. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202. AIDS Clin Care. 2008;20(4):28.
   Google Scholar
• Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treat-ment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10)1273–1281.
   Web of Science ®Google Scholar
• Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymi-dine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22(16):2155–2163.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;23(15):1971–1975.
   PubMed Web of Science ®Google Scholar
• Jones R, Stebbing J, Nelson M et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37(4):1489–1495.
   PubMed Web of Science ®Google Scholar
• Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: A retro-spective cohort study. HIV Med. 2005;6(4):284–290.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Návoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf. 2010;9(4):545–559.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40(8)1194–1198.
   Web of Science ®Google Scholar
• Winston J, Deray G, Hawkins T, Szczech L, Wyatt C, Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis. 2008;47(11):1449–1457.
   PubMed Web of Science ®Google Scholar
• Stohr W, Reid A, Walker AS, et al. Glomerular dysfunc-tion and associated risk factors over 4–5 years follow-ing antiretroviral therapy initiation in Africa. Antivir Ther. 2011;16(7)1 011–1020.
   Web of Science ®Google Scholar